Floatz logo

VONOPRAZAN

HELICOBACTER PYLORI INFECTIONS

Nanjing First Hospital, Nanjing Medical UniversitySmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the HELICOBACTER PYLORI INFECTIONS cohort.

Asset / SponsorPhaseRating
Amoxicillin
Nanjing First Hospital, Nanjing Medical University
Phase 4BB
Bifidobacterium tetravaccae
Nanjing First Hospital, Nanjing Medical University
Phase 4BB
UMBELLATINE
Nanjing First Hospital, Nanjing Medical University
Phase 4BB

Same molecule, other indications

VONOPRAZAN is also rated in:

esophageal varicesDormant
B
Indicative ·
60 / 100
View asset →
Metabolic SyndromeDormant
B
Indicative ·
59 / 100
View asset →
cirrhosis of liverDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →